Nabil Ismaili, Director of Medical Oncology and Radiotherapy Department at Mohammed VI University of Sciences and Health , shared a post on LinkedIn:
“Game-changing algorithms for early HR+ breast cancer in 2025!
- Neoadjuvant: Ribociclib+Letrozole (RIBOLARIS) to guide chemo de-escalation.
- Adjuvant: Giredestrant (lidERA) shows a 30% reduction in recurrence risk.
- Supportive: Elinzanetant for VMS.”
Title: A Systematic Review of Major Advances in Breast Cancer Therapeutics in 2025: Synthesis of Conference and Published Evidence
Author: Nabil Ismaili
Read the Full Article.
Other articles about breast cancer on OncoDaily.
